Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.4497
-0.0003 (-0.07%)
Jul 29, 2026, 10:25 AM EDT - Market open
Pasithea Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
15.03M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 15.06K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 12.88M |
| Moolec Science | 7.83M |
| OSR Health | 2.63M |
| Cyclerion Therapeutics | 1.99M |
| SeaStar Medical Holding | 1.44M |
| Lexaria Bioscience | 194.00K |
| Vyome Holdings | 152.72K |
KTTA News
- 8 days ago - Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026 - GlobeNewsWire
- 21 days ago - Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - GlobeNewsWire
- 4 weeks ago - Pasithea Therapeutics announces updated data from PAS-004 trial - TheFly
- 4 weeks ago - Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - GlobeNewsWire
- 6 weeks ago - Pasithea Therapeutics announces amendments to PAS-004 clinical study - TheFly
- 6 weeks ago - Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial - GlobeNewsWire
- 6 weeks ago - Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference - GlobeNewsWire
- 6 weeks ago - Pasithea Therapeutics Transcript: Transcript - Transcripts